UPDATE 2-Gilead wins U.S. nod for drug for all types of hepatitis C

June 28 (Reuters) - U.S. health regulators on Tuesday

approved a combination drug by Gilead Sciences Inc that

is the first available treatment for all six major forms of

hepatitis C, advancing the company's leadership in the field and

sending its shares up more than 4 percent.

Read more